



澳門大學
UNIVERSIDADE DE MACAU
UNIVERSITY OF MACAU



何鴻燊博士醫療拓展基金會
Dr. Stanley Ho Medical Development Foundation

澳門大學—何鴻燊博士醫療拓展基金會

University of Macau – Dr. Stanley Ho Medical Development Foundation

“揚帆追夢、創啟未來” 2023年度獲資助研究項目

“SET SAIL FOR NEW HORIZONS, CREATE THE FUTURE” FUNDED PROJECT FOR 2023

促腫瘤免疫治療的國重實驗室之行 A trip to the National Laboratory for Promoting Tumor Immunotherapy



趙琦教授
Prof. Qi ZHAO


趙琦，澳門大學健康科學學院生物醫學系副教授。曾承擔國家科技部重點研發計劃、澳門科學技術發展基金與國家自然科學基金委員會聯合科研資助、鍾南山醫學基金等。曾榮獲過美國NIH聯邦技術轉讓獎和深圳海外高層次人才。

Qi ZHAO is an Associate Professor at the Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau. He has undertaken National Key Research and Development Project, Joint Scientific Research Project Funding by the National Natural Science Foundation of China and the Macao Science and Technology Development Fund and Zhong Nanshan Medical Fund. He has won the US NIH Federal Technology Transfer Award and the Shenzhen Overseas High-Level Talent Award.

趙教授與四川大學生物治療國家重點實驗室展開了合作研究，進一步加強了兩所大學在多個免疫治療領域的研究合作。在科學研究方面，我們發現了針對軟組織肉瘤的藥物治療標靶，並創造了CAR-T細胞治療的3D評估技術。我們在知名期刊如《Clinical Cancer Research》（被媒體報道）、《Journal of Controlled Release》（期刊封面和亮點）等發表了5篇論文，進一步擴大了何鴻燊博士醫療拓展基金會在全球範圍內的影響力。在學術合作方面，澳門大學與四川大學的團隊共同擔任了《Seminars in Cancer Biology》（影響因子IF=14.5）期刊的主編職位。在臨床轉化研究方面，我們獲得了新抗腫瘤藥物早期臨床前開發的重要資訊。

Professor ZHAO conducted collaborative research at the State Key Laboratory of Biotherapy, Sichuan University. This visit has further strengthened the research collaboration between two Universities in various fields of immunotherapy. We identified therapeutic targets for soft tissue sarcomas and developed a 3D assessment technique for CAR-T cell therapy. We published five papers in renowned journals, including Clinical Cancer Research and Journal of Controlled Release (with journal covers and highlights), which have expanded the global impact of the Dr. Stanley Ho Medical Development Foundation. Two teams from the University of Macau and Sichuan University jointly served as editors for Seminars in Cancer Biology (with an impact factor of IF=14.5). We have gained valuable insights into early preclinical development procedures for new anti-tumor drugs.

國家重點實驗室訪問 A trip to the national laboratory
CAR-T細胞治療的3D評估技術 3D assessment technique for CAR-T cell therapy
知名期刊擴大了基金會在全
球範圍內的影響力。 Expand the global impact of the Foundation



CLINICAL CANCER RESEARCH | TRANSGLIATIONAL CANCER MECHANISMS AND THERAPY

Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma

Application of Artificial Intelligence in Oncology
Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment